Home/Pipeline/RV-8451

RV-8451

Obesity

PreclinicalActive

Key Facts

Indication

Obesity

Phase

Preclinical

Status

Active

Company

Rivus Pharmaceuticals

About Rivus Pharmaceuticals

Rivus Pharmaceuticals is a private, clinical-stage biotech founded in 2019 and headquartered in Durham, North Carolina. The company is pioneering a new class of oral therapeutics based on mitochondrial uncoupling and GLP-1 agonism to treat obesity and its comorbidities. Its lead asset, HU6, has successfully completed three Phase 2 trials, demonstrating efficacy in MASLD, MASH, and HFpEF. Rivus is advancing a pipeline that includes a differentiated GLP-1 candidate, positioning it in the large and rapidly growing obesity and metabolic disease market.

View full company profile

Therapeutic Areas

Metabolic Diseases Obesity MASH Cardiometabolic Diseases

Other Obesity Drugs

Drug	Company	Phase	Status
LET003	Harbour BioMed	Discovery	Active (Global)
LET001	Harbour BioMed	Discovery	Active (Global)
RGT-075	Regor Therapeutics	Phase 2b	Active
Anti‑Obesity Oral Drug	Premas Biotech	Phase 1	Active
Obesity Target Discovery Collaboration	Fauna Bio	Target Discovery/Preclinical	Active
GLP-1 variants	Heligenics	Discovery	Active
MYO Platform (Metabolic Disease)	Renbio	Pre-clinical	Active
Obesity Clinical Trials	IMA Clinical Research	Not Applicable (Service)	Active
KAYO-2000	KayoThera	Preclinical	Active
MVD-1 (SANA)	Eolo Pharma	Phase 1	Active
GIP-neutralizing antibody	Helicore Biopharma	Pre-clinical	Active
Antral Gastroplasty / Endoscopic Sleeve	Endo-TAGSS	Pre-clinical	Active